PRLD: Prelude Therapeutics Inc Company Profile & Statistics

About

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. It is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorporated is based in Wilmington, United States.

Info & Links

CEO

Krishna Vaddi

Headquarters

175 Innovation Boulevard
Wilmington, DE 19805, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

128

Prelude Therapeutics Inc Statistics

Valuation Measures

Market Capitalization²

62.46M

Enterprise Value

51.68M

Enterprise Value/EBITDA(ttm)

-0.35

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

0.43

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

-268.93%

Return on Equity(ttm)

-66.89%

Return on Invested Capital(ttm)

-68.55%

Return on Assets(ttm)

-55.59%

Income Statement

Revenue(ttm)

3.00M

Revenue Per Share(ttm)

0.05

Gross Profit(ttm)

3.00M

EBITDA(ttm)³

-146.41M

Net Income Available to Common(ttm)

-131.52M

Diluted EPS(ttm)

-1.78

Share Statistics

Beta (5Y Monthly)

1.39

52-Week Change

-64.53%

S&P 500 52-Week Change

25.78%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

55.04M

Dividend Yield

0.00%

Float⁴

20.47M

% Held by Insiders

62.80%

% Held by Institutions

79.72%

Balance Sheet

Total Cash(mrq)

153.63M

Total Cash Per Share(mrq)

2.79

Total Debt(mrq)

359.00K

Total Debt/Equity(mrq)

0.23%

Current Ratio(mrq)

7.04%

Quick Ratio(mrq)

7.04%

Book Value Per Share(mrq)

2.84

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.08

Free Cash Flow(ytd)

-82.86M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

PRLD

Prelude Therapeutics Inc

Prelude Therapeutics Inc Profile